NCT02720510 · OUTCOME

Duration of Response

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) · Source last updated 2018-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From measurable response to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

Analysis population: The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.

Groups in this outcome

Arm 1 - RVD + Pan

Revlimid, Velcade, dexamethasone and Farydak

Arm 2 - RVD

Revlimid, Velcade and Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm 1 - RVD + Pan	0
Arm 2 - RVD	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

groups

description
Revlimid, Velcade, dexamethasone and Farydak
id
OG000
title
Arm 1 - RVD + Pan
description
Revlimid, Velcade and Dexamethasone
id
OG001
title
Arm 2 - RVD

population Description

The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.

reporting Status

POSTED

time Frame

From measurable response to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

title

Duration of Response

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice